News

New Kits for Patients with Multiple Myeloma

18 Aug 2010
Sarah Sarah
Marketing / Sales

Product news

Binding Site has launched 4 more Hevylite™ kits. Hevylite is CE marked for use in monitoring patients with Multiple Myeloma and other B cell dyscrasias.

Hevylite IgA Kappa and Hevylite IgA Lambda are now available on Binding Site’s specialist protein analyser, SPAPLUS. Hevylite IgG Kappa and Hevylite IgG Lambda are also now available for the Siemens BNII™analyser. Results obtained using the Hevylite IgA Kappa and IgA Lambda assays for the Siemens BNII, launched in 2009, are already proving to be a clinically useful tool for monitoring these patients.

Hevylite is a panel of immunoassays using polyclonal antibodies targeted at unique junctional epitopes between heavy chain and light chain constant regions of intact immunoglobulins. The immunoassays can separately identify the different light chain types of each immunoglobulin class, i.e. IgAκ, IgAλ, IgGκ, IgGλ, IgMκ and IgMλ. These molecules are then measured in pairs, e.g. IgAκ/IgAλ, to produce ratios of monoclonal/background polyclonal immunoglobulin concentrations, in the same manner as serum free light chain κ/λ ratios (Freelite). These new automated assays offer increased sensitivity over serum protein electrophoresis for quantifying monoclonal immunoglobulins.

Tags

Point-of-CarePoint-of-Care Testing (POCT) or Near Patient Testing (NPT) products are available for urine, blood and other clinical chemistry analyses. POCT includes: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing (PT / INR), rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing and cholesterol screening.Clinical TrialsClinical Trials, an essential part of drug discovery process, assess the safety and effectiveness of a new medication or device in the pharmaceutical industry. Clinical Trials are a phased process (Phase 0, Phase I, Phase II, Phase III and Phase IV) which begins after initial preclinical testing.
New Kits for Patients with Multiple Myeloma